Therapy Areas: Cardiovascular
Bryn Pharma Appoints Whitaker to Its Board of Directors
2 September 2021 - - US-based pharmaceutical company Bryn Pharma, LLC has appointed Anne Clem Whitaker to its board of directors, effective immediately, the company said.

Whitaker brings more than 30 years of extensive leadership and commercialization experience in pharmaceuticals, consumer products and medical devices to Bryn's board.

She has held senior-level executive leadership roles at Sanofi, GlaxoSmithKline, Bausch Health, and multiple CEO roles for private and public development stage companies.

Most recently, Whitaker served as CEO of Aerami Therapeutics before taking on the chair of the board position in November 2020.

Whitaker currently serves as a healthcare-focused advisor for private equity firms and as an independent director on the board of three public companies including Faron Pharmaceuticals (FARN: LSE), Caladrius (CLBS: NASDAQ), and Mallinckrodt.

She also serves on the board of Curio Digital Therapeutics, Inc., a privately held women's health focused digital therapeutics company and the board of Trustees for the University of North Alabama.

Prior to joining Aerami, Whitaker served in multiple C-suite roles for emerging biotechnology and specialty pharmaceutical companies.

Prior to these roles, Whitaker served as the North America Pharmaceutical Region Head and president for Sanofi from 2011 to 2014, and as senior vice president from 2008 to 2011 at GlaxoSmithKline, where she ran their Cardiovascular, Metabolic and Urology business in the US.

From 1992 to 2008, Whitaker held several commercial roles at GSK and a senior level global role as the senior vice president, Head of the Organizational and Leadership Development Center of Excellence based in London.

Whitaker started her career in the pharmaceutical industry as a pharmaceutical sales representative for the Upjohn company after receiving her Bachelor of Science from the University of North Alabama.

Bryn Pharma is a privately held pharmaceutical company focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients.